Accession Number : AD1046524


Title :   A Phase 1 Trial of an Immune Checkpoint Inhibitor plus Stereotactic Ablative Radiotherapy in Patients with Inoperable Stage I Non-Small Cell Lung Cancer


Descriptive Note : Technical Report,30 Sep 2016,29 Sep 2017


Corporate Author : University Of California, Davis Davis United States


Personal Author(s) : Kelly, Karen ; Monjazeb,Arta ; Daly,Megan ; Eastham,David


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1046524.pdf


Report Date : 01 Oct 2017


Pagination or Media Count : 10


Abstract : This clinical trial is the first to evaluate the synergy between radiation, a well-known immune modulator, with the novel immune checkpoint inhibitor MPDL3280A (atezolizumab) in early stage inoperable non-small cell lung cancer. The trial is comprised of a traditional 3 3 phase I design followed by a dose expansion. We have enrolled 3 patients into dose level 1.Two patients have completed the entire treatment plan and 1 patient is in the 9-week dose limiting time period. The regimen has been well tolerated with no dose limiting toxicities observed in the first two patients. One patient had a partial response and the other patient has stable disease. Interestingly patient 1 had tumor shrinkage after two cycles of low dose MPDL3280A without the radiation. The trial continues as planned.


Descriptors :   lung cancer , INHIBITORS , metastasis , immunotherapy , radiotherapy , CLINICAL TRIALS , tumor cell line , immune system


Subject Categories : Medicine and Medical Research
      Pharmacology


Distribution Statement : APPROVED FOR PUBLIC RELEASE